Sign up Australia
Proactive Investors - Run By Investors For Investors

MMJ Phytotech CEO will outline medicinal cannabis strategy at CEO Session

The company has this week entered into a cannabis concentrate program agreement with a Canadian company.
Cannabis and medicinal cannabis products
Jason Conroy will present at the CEO Session in Sydney on October 22

MMJ PhytoTech Ltd (ASX:MMJ) has an active strategy in the medicinal cannabis sector which chief executive officer Jason Conroy will outline at the Proactive CEO Sessions in Sydney on Monday, October 22.

The company recently confirmed the disposal of subsidiary PhytoTech Therapeutics Ltd (PTL) to Harvest One Cannabis Inc (TSX-V:HVT), which led to suspension from the ASX.

READ: MMJ PhytoTech applies for ASX re-quotation, Canadian cannabis investment enters distribution agreement

A re-quotation application has been made, which also incorporates a change of name to MMJ Group Holdings Limited.

This week the company has confirmed that its investment MediPharm Labs Inc (TSX-V:LABS) entered into a cannabis concentrate program agreement with Emerald Health Therapeutics Inc (TSX-V:EMH).

MMJ’s investment in MediPharm amounts to C$5 million, comprising 5.88 million shares at 85 Canadian cents per share and 2.94 million warrants exercisable at C$1.20 a share by October 2020.

This agreement enables Emerald to provide pharmaceutical-grade cannabis concentrate products produced by MediPharm to its large base of registered patients as well as premium concentrates for adult-use recreational consumers.

MediPharm is focused on downstream secondary extraction methodology, distillation and cannabinoid isolation and purification.

The company operates of one the largest cannabis concentrate manufacturing facilities in Canada and is built current good manufacturing practices and ISO standards.

Divestment notice lodged

Today MMJ announced that it has lodged a notice with the TSX Venture Exchange stating its intention to divest up to 5 million of its 53.333 million shares held in Harvest One.

The notice is a Canadian regulatory requirement as MMJ’s shareholding of approximately 30% in Harvest One is more than the 20% ownership threshold.

On completion of the sale of PTL, MMJ’s shareholding in Harvest One will increase by the equivalent of C$6.86 million divided by the 10-day volume weighted average price of Harvest One shares preceding settlement of that sale.

Conroy said, “After being fully-invested since the end of July, and with a significant shareholding in Harvest One that will increase on completion of the PTL sale, it is prudent to be ready and able to trim our ownership stake so we can participate in other cannabis sector investment opportunities as they arise.”

Register for the CEO Session today to find out more.

Sydney details, Monday, October 22, 2018

Also featuring will be Yandal Resources Limited (ASX:YRL), High Peak Royalties Ltd (ASX:HPR), Minotaur Exploration Ltd (ASX:MEP) and The Hydroponics Company Ltd (ASX:THC).

Join our Crypto, Blockchain and Cannabis Telegram group here
View full MMJ profile View Profile

MMJ PhytoTech Ltd Timeline

Newswire
December 11 2017
Newswire
November 10 2017

Related Articles

1539364967_Cannabis-plant.jpg
October 10 2018
Management behind ICC International Cannabis Corp has a clear buy, build and sell strategy
cannabis
August 28 2018
Tidal Royalty provides capital to help grow licenced US cannabis firms in exchange for receiving a percentage of future top-line revenues.

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use